Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Apr:159:56-61.
doi: 10.1016/j.jad.2014.02.017. Epub 2014 Feb 18.

Do the dissociative side effects of ketamine mediate its antidepressant effects?

David A Luckenbaugh  1 , Mark J Niciu  1 , Dawn F Ionescu  1 , Neal M Nolan  1 , Erica M Richards  1 , Nancy E Brutsche  1 , Sara Guevara  1 , Carlos A Zarate  2
Affiliations

Do the dissociative side effects of ketamine mediate its antidepressant effects?

David A Luckenbaugh et al. J Affect Disord. 2014 Apr.

Abstract

Background: The N-methyl-d-aspartate receptor antagonist ketamine has rapid antidepressant effects in major depression. Psychotomimetic symptoms, dissociation and hemodynamic changes are known side effects of ketamine, but it is unclear if these side effects relate to its antidepressant efficacy.

Methods: Data from 108 treatment-resistant inpatients meeting criteria for major depressive disorder and bipolar disorder who received a single subanesthetic ketamine infusion were analyzed. Pearson correlations were performed to examine potential associations between rapid changes in dissociation and psychotomimesis with the Clinician-Administered Dissociative States Scale (CADSS) and Brief Psychiatric Rating Scale (BPRS), respectively, manic symptoms with Young Mania Rating Scale (YMRS), and vital sign changes, with percent change in the 17-item Hamilton Depression Rating scale (HDRS) at 40 and 230min and Days 1 and 7.

Results: Pearson correlations showed significant association between increased CADSS score at 40min and percent improvement with ketamine in HDRS at 230min (r=-0.35, p=0.007) and Day 7 (r=-0.41, p=0.01). Changes in YMRS or BPRS Positive Symptom score at 40min were not significantly correlated with percent HDRS improvement at any time point with ketamine. Changes in systolic blood pressure, diastolic blood pressure, and pulse were also not significantly related to HDRS change.

Limitations: Secondary data analysis, combined diagnostic groups, potential unblinding.

Conclusions: Among the examined mediators of ketamine׳s antidepressant response, only dissociative side effects predicted a more robust and sustained antidepressant. Prospective, mechanistic investigations are critically needed to understand why intra-infusion dissociation correlates with a more robust antidepressant efficacy of ketamine.

Keywords: Bipolar depression; Blood pressure; Ketamine; Major depressive disorder; Predictors; Psychotomimetic.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest

Zarate is listed as a co-inventor on a patent application for the use of ketamine and its metabolites in major depression. Dr. Zarate has assigned his rights in the patent to the U.S. government but will share a percentage of any royalties that may be received by the government. The remaining authors have no conflict of interest to disclose, financial or otherwise.

Figures

Fig. 1
Fig. 1
Infusion day (up to 230 min post-infusion) baseline-corrected clinical ratings from 108 treatment-resistant patients with major depression who received a single subanesthetic dose (0.5 mg/kg for 40 min) for treatment-resistant major depression. A. 17-item Hamilton Depression Rating Scale (HDRS), B. Clinician-Administered Dissociative Scale (CADSS), C. Brief Psychiatric Rating Scale (BPRS) Positive Symptoms Subscale, and D. Young Mania Rating Scale (YMRS); *=p<0.05.
Fig. 2
Fig. 2
Intra-ketamine infusion (every 5 min) baseline-corrected vital sign recordings from 108 treatment-resistant patients with major depression who received a single subanesthetic dose (0.5 mg/kg for 40 min) for treatment-resistant major depression. A. Diastolic Blood Pressure, B. Systolic Blood Pressure, and C. Pulse; *=p<0.05.
Fig. 3
Fig. 3
Pearson Correlations with Clinician-Administered Dissociative States Scale (CADSS) at 40 min Post-Ketamine Infusion with 17-item Hamilton Depressing Rating Scale (HDRS) scores at A. 230 min Post-Ketamine Infusion; B. Day 1 Post-Ketamine Infusion; and C. Day 7 Post-Ketamine Infusion. The strength of the correlation is presented with significance level set at p<0.05 (bolded).
See this image and copyright information in PMC

References

    1. Aalto S, Hirvonen J, Kajander J, Scheinin H, Nagren K, Vilkman H, Gustafsson L, Syvalahti E, Hietala J. Ketamine does not decrease striatal dopamine D2 receptor binding in man. Psychopharmacol (Berl) 2002;164:401–406. - PubMed
    1. Aalto S, Ihalainen J, Hirvonen J, Kajander J, Scheinin H, Tanila H, Nagren K, Vilkman H, Gustafsson LL, Syvalahti E, Hietala J. Cortical glutamate–dopamine interaction and ketamine-induced psychotic symptoms in man. Psychopharmacol (Berl) 2005;182:375–383. - PubMed
    1. aan het Rot M, Collins KA, Murrough JW, Perez AM, Reich DL, Charney DS, Mathew SJ. Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression. Biol Psychiatry. 2010;67:139–145. - PubMed
    1. Aan Het Rot M, Zarate CA, Charney DS, Mathew SJ. Ketamine for depression: where do we go from here? Biol Psychiatry. 2012;72:537–547. - PMC - PubMed
    1. Adams BW, Bradberry CW, Moghaddam B. NMDA antagonist effects on striatal dopamine release: microdialysis studies in awake monkeys. Synapse. 2002;43:12–18. - PubMed

Publication types